$235.50-1.64 (-0.69%)
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.
Quest Diagnostics Incorporated in the Healthcare sector is trading at $235.50 with a market capitalization of $25.9B. Wall Street consensus targets $245.87 (15 analysts), implying a +4.4% move over the next 12 months. The stock is currently near its 52-week high of $247.19, remaining 17.6% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.04B↑ | $2.90B↑ | $2.81B↓ | $2.82B↑ | $2.76B |
| Gross Profit | $1.03B↑ | $942.00M↑ | $910.00M↓ | $949.00M↑ | $943.00M |
| Operating Income | $459.00M↑ | $404.00M↑ | $386.00M | $386.00M↓ | $438.00M |
| Net Income | $320.00M↑ | $252.00M↑ | $245.00M | $245.00M↓ | $282.00M |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, a...

Testing for Alzheimer’s-related brain changes has traditionally depended on procedures that can be expensive, invasive, or difficult to access. Roche Holding AG and Eli Lilly and Company (NYSE:LLY) may now have a simpler way to help physicians evaluate certain patients. The FDA has cleared Elecsys pTau217, which is a blood test that helps identify whether […]

In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Its deepest fall inside a market shock is not its deepest fall, and that gap is what a holder should size for.

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Academic risk and quality models computed from DGX's own filings and price history, not from analyst opinion.
Strong on 8 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 22.8% reading.
Fama-French 5-factor market beta. The five factors explain 11% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.